Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | MMP2 | P08253 | 2/20 | 0.34 |
| ▸ | ANPEP | P15144 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.33 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13920516 | 1.00 | ATM (0.41) | ATMALDH1A1FKBP1AKMT2AMEN1 | |
| SCHEMBL12705543 | 0.86 | ANPEP (0.50) | ALDH1A1FKBP1AKMT2AMEN1MMP2 | |
| SCHEMBL4368576 | 0.85 | ATM (0.59) | ATMALDH1A1FKBP1AKMT2AMEN1 | |
| SCHEMBL12705546 | 0.84 | FKBP1A (0.36) | ALDH1A1FKBP1AKMT2AMEN1MAPT | |
| SCHEMBL14377801 | 0.81 | ALDH1A1 (0.57) | ATMALDH1A1KMT2AMEN1MMP2 | |
| SCHEMBL25109725 | 0.80 | FKBP1A (0.39) | ATMALDH1A1FKBP1AKMT2AMEN1 | |
| SCHEMBL2202494 | 0.79 | POLB (0.50) | ATMALDH1A1FKBP1AKMT2AMEN1 | |
| SCHEMBL3041685 | 0.79 | POLB (0.50) | ATMALDH1A1FKBP1AKMT2AMEN1 | |
| SCHEMBL9635522 | 0.79 | POLB (0.50) | ATMALDH1A1FKBP1AKMT2AMEN1 | |
| SCHEMBL116396 | 0.79 | POLB (0.50) | ATMALDH1A1FKBP1AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919505-B2 | Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound | SCHERING CORPORATION (US) | 2011-04-05 | — | — | US | disclosed |
| US-7511062-B2 | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-20080027101-A1 | XINAFOATE SALT OF A SUBSTITUTED 5-OXAZOL-2-YL-QUINOLINE COMPOUND | SCHERING CORPORATION | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027101-A1 | XINAFOATE SALT OF A SUBSTITUTED 5-OXAZOL-2-YL-QUINOLINE COMPOUND | XDH, UPF1, NOX5 | ATM 4197/4885ALDH1A1 940/4885FKBP1A 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.